Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study For Convivia(TM)

Raptor Pharmaceuticals Corp. (”Raptor” or the “Company”) (OTC Bulletin Board: RPTP), announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. (”Bennu”), has initiated the Company’s first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole (”4-MP”) in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia(TM) program.

More: continued here

Filed under: Alcohol / Addiction / Illegal Drugs on April 22nd, 2008